Sheila Anne Bobis, PA
Physician Assistant · Riverside, CANPI 1083024699
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $37,446 of the $54,578 with a category attached, or 68.6%. 21 manufacturers reported payments, led by AbbVie at 59.3% of the total. Reporting peaked in 2022 at $23,335 and has fallen 61.1% since, to $9,076 in 2025. Among physician assistant clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 613 payments — averaging $89.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$32K
- Biohaven Pharmaceutical Holding Company Ltd.$8K
- Biohaven Pharmaceuticals, Inc.$6K
- Pfizer$3K
- Teva Pharmaceuticals USA, Inc.$2K
- Axsome Therapeutics, Inc.$619
- plus $2K from 15 others
What the payments were for
- Speaking & faculty fees$37,44669%
- Travel & lodging$4,7959%
- Food & beverage$12,23622%
- Education$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 249 | $32,382 |
| Biohaven Pharmaceutical Holding Company Ltd. | 40 | $8,010 |
| Biohaven Pharmaceuticals, Inc. | 39 | $6,371 |
| Pfizer | 59 | $2,925 |
| Teva Pharmaceuticals USA, Inc. | 94 | $1,896 |
| Axsome Therapeutics, Inc. | 12 | $619 |
| Amgen | 21 | $513 |
| Scilex Pharmaceuticals Inc. | 20 | $339 |
| Supernus Pharmaceuticals, Inc. | 17 | $324 |
| Lundbeck LLC | 18 | $319 |
| Lilly USA, LLC | 16 | $303 |
| Argenx US, Inc. | 8 | $137 |
| Novartis | 6 | $136 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $89 |
| UCB, Inc. | 3 | $71 |
| EMD Serono, Inc. | 2 | $44 |
| AstraZeneca | 1 | $25 |
| Sanofi | 1 | $20 |
| Biogen | 1 | $20 |
| Amneal Pharmaceuticals LLC | 1 | $19 |
| MDD US Operations, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$23,873
- NURTEC ODT$15,118
- QULIPTA$8,812
- Symbravo$372
How this compares
$54,578 in reported general payments places this provider in the 95th percentile of 10,423 physician assistant providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UbrelvyUbrogepant | 199 | $230,000 |
| Nurtec OdtRimegepant Sulfate | 170 | $221,817 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 80 | $57,955 |
| Aimovig AutoinjectorErenumab-Aooe | 52 | $39,193 |
| BotoxOnabotulinumtoxina | 26 | $32,099 |
| QuliptaAtogepant | 28 | $29,171 |
| ElyxybCelecoxib | 32 | $26,890 |
| Emgality PenGalcanezumab-Gnlm | 27 | $22,439 |
| Nortriptyline Hcl | 115 | $1,887 |
| Divalproex Sodium ErDivalproex Sodium | 38 | $942 |
| Gabapentin | 41 | $738 |
| Primidone | 36 | $562 |
| Topiramate | 55 | $438 |
| Propranolol Hcl | 32 | $437 |
| Propranolol Hcl ErPropranolol Hcl | 13 | $406 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Botox, Qulipta | $32,382 | $291,271253 claims |
| PfizerNurtec Odt | $2,925 | $221,817170 claims |
| Scilex Pharmaceuticals Inc.Elyxyb | $339 | $26,89032 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,423 physician assistant providers in California.
Other physician assistant in Riverside
- Robert FontanillaRiverside$32K
- Andrea NguyenIrvine$1M
- Mikhail AlperMadera$889K
- Erin JensenUpland$716K
- Franklin ClineSacramento$458K
- Carla CrespoMarina del Rey$297K
- Katherine OsakiEl Centro$274K
- Shawna JonesFountain Valley$266K
- Heather AustinSalinas$219K
- Andrea FoxStanford$172K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.